Communal work

Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Medical Supplies, Insulin glargine, Insulin, Partnership, Insulin lispro, Medication, Patient, Insulin aspart, NKF, FDA, Pharmaceutical industry, Communal work

THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.

Key Points: 
  • THDB and NKF entered into strategic cooperation and will be jointly responsible for the development and supply of the three products.
  • Upon approval, THDB, NKF and Meitheal will receive royalties on all product sales in the United States.
  • “This collaboration reinforces the strength of NKF’s partnership with Meitheal and demonstrates our commitment to innovation and continued investment in our portfolio companies,” said Eric Tang, President of NKF.
  • “We look forward to bringing these three products one step closer to patients through this strategic partnership.”

Meitheal is Ranked #4 on Crain’s 2023 Fast 50 in Chicago

Retrieved on: 
Thursday, June 22, 2023
Biotechnology, Pharmaceutical, Health, Medication, University of Chicago Booth School of Business, Patient, News, NKF, Pharmaceutical industry, Communal work

Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, is proud to be ranked #4 on Crain’s Chicago Business 2023 Fast 50.

Key Points: 
  • Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, is proud to be ranked #4 on Crain’s Chicago Business 2023 Fast 50.
  • “Meitheal was among a variety of companies showcased that have demonstrated significant revenue growth in a five-year period,” said CEO Tom Shea.
  • The Fast 50 provides a full ranking and exclusive profiles on Chicago’s fastest-growing companies in 2023.
  • Looking to grow your career at a company that puts its people first?

Meitheal Pharmaceuticals Earns Great Place to Work Certification™ and is Named One of Best Places to Work in Illinois

Retrieved on: 
Tuesday, July 19, 2022
Health, General Health, Culture, Research, Feedback, Syringe, Gaps, Employment, Patient, Communication, BCG, Workplace, Review, Medication, Certification, Workforce, Great Places, Sale, US Foods, The Last Best Place, FDA, Anticoagulant, Pharmaceutical industry, Management, Communal work

Meitheal was also recently named as one of the 2022 Best Places to Work in Illinois, presented by The Daily Herald Suburban Business.

Key Points: 
  • Meitheal was also recently named as one of the 2022 Best Places to Work in Illinois, presented by The Daily Herald Suburban Business.
  • Great Place to Work is a prestigious award based entirely on what current employees say about their experience working at Meitheal.
  • Great Place to Work Certification isnt something that comes easily it takes ongoing dedication to the employee experience, said Sarah Lewis-Kulin, vice president of global recognition at Great Place to Work.
  • The Best Places to Work in Illinois is a survey competition to determine which participants are the states best employers.